MRD response after early consolidation chemotherapy (TP2 MRD) and blinatumomab 1 (TP3 MRD) in 109 MRD-evaluable patients with paired TP2-TP3 samples
| MRD evaluation at TP3 (blinatumomab) . | ||||
|---|---|---|---|---|
| Characteristic . | Overall, n (%) . | MRD– . | MRD+ . | P value∗ . |
| MRD evaluation at TP2 | <.001 | |||
| MRD– | 79 (72.4) | 101 (93) | 1 (0.9) | |
| MRD+ | 30 (28.3) | — | 7 (6.4) | |
| MRD evaluation at TP3 (blinatumomab) . | ||||
|---|---|---|---|---|
| Characteristic . | Overall, n (%) . | MRD– . | MRD+ . | P value∗ . |
| MRD evaluation at TP2 | <.001 | |||
| MRD– | 79 (72.4) | 101 (93) | 1 (0.9) | |
| MRD+ | 30 (28.3) | — | 7 (6.4) | |
| Age group, y . | |||||
|---|---|---|---|---|---|
| . | Overall, n (%) . | 18-39, n = 54 . | 40-55, n = 42 . | >55, n = 13 . | P value∗ . |
| MRD evaluation at TP2 | .69 | ||||
| MRD– | 79 (72) | 38 (70) | 30 (71) | 11 (85) | |
| MRD+ | 30 (28) | 16 (30) | 12 (29) | 2 (15) | |
| MRD evaluation at TP3 | .50 | ||||
| MRD– | 101 (93) | 48 (89) | 40 (95) | 13 (100) | |
| MRD+ | 8 (7.3) | 6 (11) | 2 (4.8) | 0 (0) | |
| Age group, y . | |||||
|---|---|---|---|---|---|
| . | Overall, n (%) . | 18-39, n = 54 . | 40-55, n = 42 . | >55, n = 13 . | P value∗ . |
| MRD evaluation at TP2 | .69 | ||||
| MRD– | 79 (72) | 38 (70) | 30 (71) | 11 (85) | |
| MRD+ | 30 (28) | 16 (30) | 12 (29) | 2 (15) | |
| MRD evaluation at TP3 | .50 | ||||
| MRD– | 101 (93) | 48 (89) | 40 (95) | 13 (100) | |
| MRD+ | 8 (7.3) | 6 (11) | 2 (4.8) | 0 (0) | |
| Risk group . | |||||
|---|---|---|---|---|---|
| . | Overall, n (%) . | SR, n = 65 . | HR, n = 21 . | VHR, n = 23 . | P value∗ . |
| MRD evaluation at TP2 | .008 | ||||
| MRD– | 79 (72) | 54 (83) | 11 (52) | 14 (61) | |
| MRD+ | 30 (28) | 11 (17) | 10 (48) | 9 (39) | |
| MRD evaluation at TP3 | .021 | ||||
| MRD– | 101 (93) | 63 (97) | 20 (95) | 18 (78) | |
| MRD+ | 8 (7.3) | 2 (3.1) | 1 (4.8) | 5 (22) | |
| Risk group . | |||||
|---|---|---|---|---|---|
| . | Overall, n (%) . | SR, n = 65 . | HR, n = 21 . | VHR, n = 23 . | P value∗ . |
| MRD evaluation at TP2 | .008 | ||||
| MRD– | 79 (72) | 54 (83) | 11 (52) | 14 (61) | |
| MRD+ | 30 (28) | 11 (17) | 10 (48) | 9 (39) | |
| MRD evaluation at TP3 | .021 | ||||
| MRD– | 101 (93) | 63 (97) | 20 (95) | 18 (78) | |
| MRD+ | 8 (7.3) | 2 (3.1) | 1 (4.8) | 5 (22) | |
Blinatumomab was administered to a total of 122 study patients (further details are provided in the text). Results are shown overall, as well as by age and clinical risk group.
Fisher exact test.